|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Pathophysiology |
A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control
1 Department of Endocrinology, Diabetes Center, Research Institute for Endocrinology, Reproduction and Metabolism, VU University Medical Center, Amsterdam, the Netherlands
2 Department of Medical Psychology, Diabetes Center, Research Institute for Endocrinology, Reproduction and Metabolism, VU University Medical Center, Amsterdam, the Netherlands
3 Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
OBJECTIVE—To assess in a randomized crossover trial the efficacy of continuous subcutaneous insulin infusion in improving glycemic control and health-related quality of life in type 1 diabetic patients with long-standing poor glycemic control.
RESEARCH DESIGN AND METHODS—A total of 79 patients in 11 Dutch centers were randomized to 16 weeks of continuous subcutaneous insulin infusion followed by 16 weeks intensive injection therapy or the reverse order. Glycemic control was assessed by HbA1c, self-reported hypoglycemic events, and blood glucose memory meter read outs. Changes in quality of life were assessed by self-report questionnaires administered at baseline and 16 weeks.
RESULTS—As the drop-out rate after crossover was high (17 of 79 patients [22%]), we analyzed the trial as a parallel clinical trial, using data of the first half of the crossover phase only. At 16 weeks, mean HbA1c was 0.84% (95% CI -1.31 to -0.36) lower in the continuous subcutaneous insulin infusion group compared with the insulin injection group (P = 0.002). Stability of blood glucose self-measurement values, expressed as SD of the nine-point blood glucose profiles, improved in the insulin pump group by 29.3 ± 41.1 vs. 8.2 ± 36.5% in the injection group (P = 0.039). The number of mild hypoglycemic episodes per patient-week was 0.99 (95% CI 0.11–1.87) higher in the insulin pump group (P = 0.028). Weight gain was similar in both groups. Scores on the Short-Form 36-Item subscales ‘general health’ and ‘mental health’ improved in the continuous subcutaneous insulin infusion group, compared with stable values in the injection group (P = 0.048 and 0.050, respectively).
CONCLUSIONS—Continuous subcutaneous insulin infusion improves glycemic control and some aspects of health-related quality of life in patients with a history of long-term poor glycemic control.
Abbreviations: DCCT, Diabetes Control and Complications Trial • SF-36, 36-Item Short-Form Survey • SMBG, self-monitoring of blood glucose
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Weinzimer, C. Ternand, C. Howard, C.-T. Chang, D. J. Becker, L. M.B. Laffel, and for the Insulin Aspart Pediatric Pump Study Group A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes Diabetes Care, February 1, 2008; 31(2): 210 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Battaglia, R. Alemzadeh, H. Katte, P. L. Hall, and L. C. Perlmuter Brief Report: Disordered Eating and Psychosocial Factors in Adolescent Females with Type 1 Diabetes Mellitus J. Pediatr. Psychol., July 1, 2006; 31(6): 552 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schade and V. Valentine Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No. Diabetes Care, June 1, 2006; 29(6): 1453 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman, L. L. Ilag, S. L. Johnson, C. L. Martin, J. Sinding, A. Al Harthi, C. D. Plunkett, F. B. LaPorte, R. Burke, M. B. Brown, et al. A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes Diabetes Care, July 1, 2005; 28(7): 1568 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lepore, A. R. Dodesini, I. Nosari, and R. Trevisan Age and A1C Are Important Clinical Predictors of Continuous Subcutaneous Insulin Infusion Efficacy in Type 1 Diabetic Patients Diabetes Care, July 1, 2005; 28(7): 1834 - 1835. [Full Text] [PDF]
|
|
|
|
|
|
R. Retnakaran, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: Modeling predicted benefits in relationship to baseline A1c Diabetes Care, July 1, 2005; 28(7): 1835 - 1836. [Full Text] [PDF]
|
|
|
|
|
|
I. B. Hirsch, B. W. Bode, S. Garg, W. S. Lane, A. Sussman, P. Hu, O. M. Santiago, J. W. Kolaczynski, and for the Insulin Aspart CSII/MDI Comparison Study G Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII Diabetes Care, March 1, 2005; 28(3): 533 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peyrot and R. R. Rubin Validity and Reliability of an Instrument for Assessing Health-Related Quality of Life and Treatment Preferences: The Insulin Delivery System Rating Questionnaire Diabetes Care, January 1, 2005; 28(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Retnakaran, J. Hochman, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c Diabetes Care, November 1, 2004; 27(11): 2590 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cersosimo Response to Schade: To pump or not to pump? Diabetes Care, March 1, 2003; 26(3): 967 - 967. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schade and V. Valentine To Pump or Not to Pump Diabetes Care, November 1, 2002; 25(11): 2100 - 2102. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |